Drugs / PF-03654746
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01028911 | Dec 2009 → May 2010 | Alzheimer disease | Pfizer | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT00730990 | May → Nov 2008 | — | Pfizer | Completed | No outcome recorded |
| Phase 22 trials · 2 missed | ||||||
| Phase 2 | NCT00531752 | Dec 2007 → Sep 2008 | attention deficit-hyperactivity disorder | Pfizer | Completed | Missed primary |
| Phase 2 | NCT00562120 | Dec 2007 → Aug 2008 | allergic rhinitis | Pfizer | Completed | Missed primary |
| Comparator or background therapy3 trials | ||||||
| Phase 1 | NCT01346163 Comparator | Apr 2009 → Nov 2010 | schizophrenia | University of Pennsylvania | Completed | No outcome recorded |
| Phase 2 | NCT01475383 Comparator | Apr 2012 | Tourette syndrome | Pfizer | Withdrawn | No outcome recorded |
| Phase 2 | NCT01006122 Comparator | Nov 2009 → Nov 2010 | hypersomnia, narcolepsy | Pfizer | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF 03654746 | “This study will look at the impact of dosing as well as ongoing treatment with an investigation medication identified as PF-03654746, on cognitive and physiologic indicators of...” NCT01346163 ↗ |
| Action | Inhibit | “Histamine H3 receptor antagonist” CHEMBL2151197 ↗1“H3 receptor antagonist” NCT01346163 ↗ |
| Modality | Small molecule | — CHEMBL2151197 ↗ |
| Route | Oral | “A single oral dose of PF-03654746 is the investigational drug being studied.” NCT00562120 ↗ |
| Target | HRH3 | “Histamine H3 receptor antagonist” CHEMBL2151197 ↗ |